Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. A new stem cell ...

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $476.95, moving +1.45% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78% ...

This was the stock's second consecutive day of gains.

AI search tools are on the rise, but SEO fundamentals remain critical. Learn how the two intersect and what it means for your ...

Vertex Pharmaceuticals (VRTX) continues to charm the market, securing a "Moderate Buy" consensus from 28 research firms.